SCHEMBL14969374

SCHEMBL14969374

CN(C)/C=C\C(=O)c1cccc(OC(F)F)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.62
HTT P42858 5/20 0.62
GAA P10253 3/20 0.62
ALDH1A1 P00352 5/20 0.58
HPGD P15428 4/20 0.58
RECQL P46063 2/20 0.55
RAB9A P51151 5/20 0.54
NPC1 O15118 2/20 0.54
POLB P06746 1/20 0.54
HSP90AA1 P07900 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
LMNA P02545 4/20 0.50
CYP1A2 P05177 2/20 0.49
CYP2C19 P33261 2/20 0.49
TDP1 Q9NUW8 1/20 0.48
ABCG2 Q9UNQ0 1/20 0.47
ALOX12 P18054 1/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8837784 0.84 ALDH1A1 (0.64) MAPTHTTGAAALDH1A1HPGD
SCHEMBL8837785 0.84 ALDH1A1 (0.64) MAPTHTTGAAALDH1A1HPGD
SCHEMBL31276346 0.84 MAPT (0.71) MAPTHTTGAAALDH1A1HPGD
SCHEMBL2162778 0.84 MAPT (0.71) MAPTHTTGAAALDH1A1HPGD
SCHEMBL2162785 0.84 MAPT (0.71) MAPTHTTGAAALDH1A1HPGD
SCHEMBL14537314 0.84 MAPT (0.71) MAPTHTTGAAALDH1A1HPGD
SCHEMBL5946453 0.81 MAPT (0.77) MAPTHTTGAAALDH1A1HPGD
SCHEMBL3610006 0.80 MAPT (0.65) MAPTHTTGAAALDH1A1HPGD
SCHEMBL5823575 0.80 MAPT (0.66) MAPTHTTGAAALDH1A1HPGD
SCHEMBL3609373 0.80 MAPT (0.65) MAPTHTTGAAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170121344-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2017-05-04 US disclosed
WO-2014089378-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2014-06-12 WO disclosed
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. (US) 2013-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections TTPA, TPMT, SLC19A2 MAPT 85/4885HTT 2588/4885GAA 1373/4885
US-20170121344-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS TTPA, TPMT, SLC19A2 MAPT 85/4885HTT 2588/4885GAA 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.